Quick Answer
Cartesian Therapeutics, Inc. reported Earnings Per Share Diluted of $5.02 (loss) per share for the year ending 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -11.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Cartesian Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 311.5%.
- Historical annual values: Fiscal year 2025: $5.02 (loss) per share | Fiscal year 2024: $4.49 (loss) per share | Fiscal year 2023: $49.76 (loss) per share | Fiscal year 2022: $0.10 per share | Fiscal year 2021: $0.22 (loss) per share | Fiscal year 2020: $0.68 (loss) per share | Fiscal year 2019: $1.22 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: